Stocks were up very slightly on Monday morning, but not enough to offset Friday’s sell-off after the Clinton email situation was brought back front and center. The earnings floodgates are open wide, and this week will mark the apex of earnings season. Investors keep proving over and over that they will buy each pullback. High valuations and a bull market that is seven and a half years old have not prevented buyers from stepping in. Investors are also looking for new ideas to generate gains or income ahead.
24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investing and trading ideas for our readers. Some of these analyst research reports cover stocks to buy, and other calls cover stocks to sell or avoid.
These are the top analyst upgrades, downgrades and initiations seen on Monday morning:
AbbVie Inc. (NYSE: ABBV) was downgraded to Neutral from Outperform and the price target was cut to $60 from $70 (versus a $57.60 prior close) at Credit Suisse. The stock has a 52-week trading range of $50.71 to $68.12 and a consensus analyst price target of $70.63.
Chevron Corp. (NYSE: CVX) was raised to Buy from Neutral and was added to the prized Conviction Buy list with a $118...